A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
Status:
Active, not recruiting
Trial end date:
2021-06-29
Target enrollment:
Participant gender:
Summary
The study will assess the safety and efficacy of single-agent MEK162 in adult patients with
locally advanced and unresectable or metastatic malignant cutaneous melanoma, harboring
BRAFV600E or NRAS mutations.